Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Zwitterionic Microgel Preservation Platform for Circulating Tumor Cells in Whole Blood Specimen

PROVIDER: PRJNA992805 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25208107_1.fastq.gz	Fastqsanger.gz
	SRR25208107_2.fastq.gz	Fastqsanger.gz
	SRR25208108_1.fastq.gz	Fastqsanger.gz
	SRR25208108_2.fastq.gz	Fastqsanger.gz
	SRR25208109_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

Project description:We report RNA sequencing data from enriched prostate circulating tumor cells (CTCs) from clinical blood specimens. The goal is to examine the stability of RNA signatures as a function of whole blood preservation. Each blood sample was split into two equal portions; one portion was processed immediately (i.e., 0 hour) for CTC isolation; the other was preserved in 4 deg C, using methods described in this publication, for 24, 48, or 72 hours prior to CTC isolation. CTCs were isolated using the CTC-iChip and processed for RNA sequencing.

2017-10-08 | GSE104209 | GEO

Project description:Whole Blood DNA Preservation

| PRJNA878673 | ENA

Circulating Tumor Cell(CTC) Isolation and Genonic varation Detection from Liquid Samples of Lung Cancer

Project description:We developed an enrichment-free, metabolic-based assay for rapid detection of tumor cells in the pleural effusion and peripheral blood samples. All nucleated cells are plated on microwell chips that contain 200,000 addressable microwells and then screened the chips. After candidate tumor cells were identified, retrieved single tumor cells with micromanipultor. To detection and analysis molecular characterization of these circulating tumor cells, we performed single cell whole genome amplification with multiple displacement amplification (MDA) technology and whole exome sequencing.

2017-02-17 | E-MTAB-4948 | biostudies-arrayexpress

To study sensitivity of a blood test to detect cancer cells in human blood for early diagnosis of cancer.

Project description:Primary outcome(s): The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter. Timepoint: Blood samples will be collected from study subjects at a single timepoint and analyzed for the number of circulating tumor cells (CTCs) within 7 days (168 Hrs) of blood collection.

| 2577775 | ecrin-mdr-crc

Gene Expression Profiling of Whole Blood: A Comparative Assessment of RNA-Stabilizing Collection Methods

Project description:Peripheral Blood gene expression is widely used in the discovery of biomarkers and development of therapeutics. Recently, a spate of commercial blood collection and preservation systems have been introduced with proprietary variations that may differentially impact the transcriptomic profiles. Comparative analysis of these collection platforms will help optimize protocols to detect, identify, and reproducibly validate true biological variance among subjects. In the current study, we tested two recently introduced whole blood collection methods, RNAgard® and PAXgene™ RNA, in addition to the traditional method of peripheral blood mononuclear cells (PBMCs) separated from whole blood and preserved in Trizol reagent. Study results revealed striking differences in the transcriptomic profiles from the three different methods that imply ex vivo changes in gene expression occurred during the blood collection, preservation, and mRNA extraction processes. When comparing the ability of the three preservation methods to accurately capture individuals’ expression differences, RNAgard® outperformed PAXgene™ RNA, and both showed significantly better individual separation of transcriptomic profiles than PBMCs. Hence, our study recommends using a single blood collection platform, and strongly cautions against combining methods during the course of a defined study.

2019-09-20 | GSE103889 | GEO

WES of CTC and associated WBC

Project description:Whole-exome sequencing of circulating tumor cells (CTCs) and CTCs associated to white blood cells

| PRJEB24623 | ENA

Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

Project description:Whole blood stabilization for the microfluidic isolation and molecular characterization of circulating tumor cells

| PRJNA412038 | ENA

CTC genome profiles

Project description:To characterize the most frequent genomic alterations in circulating tumor cells in breast cancer using a paired tumor-normal approach. Each normal sample was obtained from the white blood cell fraction of a patient's blood from which corresponding circulating tumor cells were isolated.

2014-02-03 | E-MTAB-2136 | biostudies-arrayexpress

Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer

Project description:Colorectal cancer (CRC) is among the most preventable cancers when precancerous lesions are detected at an early stage. Current screening methods for CRC require bowel prep or stool-based testing that are inconvenient, resulting in low compliance. Stool based tests have limited sensitivity for the detection of precancerous lesions. The CMx platform has been showed to be able to the detection of Circulating Tumor Cells (CTCs) in high sensitivity and specificity. In published studies, circulating Tumor Cells (CTCs) are captured and quantified in advanced-stages of colorectal cancer. In order to detect early and pre-cancer circulating tumor cells, we have developed an Automated Liquid Biopsy Platform that improves the detection of CTCs in early cancer stages. Therefore, this study goals are: 1) to establish a standard detection process utilizing the Automated Liquid Biopsy Platform. 2) Parallel comparison of laboratory manual operation and Automated Liquid Biopsy Platform. 3) Verify the feasibility of use of an Automated Liquid Biopsy Platform in the clinical setting.

| 2269165 | ecrin-mdr-crc

Reanalysis of transcriptomic profiling of isolated CTC from 31 patients

Project description:The CTC-iChip microfluidic device [PMID: 23552373 ] enables isolation of rare viable circulating tumor cells (CTCs) directly from whole blood specimens of patients with cancer. Reanalysis of freshly isolated CTC from 31 women with hormone receptor positive metastatic breast cancer.

2023-06-20 | GSE215886 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data